Skip to content
← Full study record

NCT00427765 · OUTCOME

Average Overall Survival Time

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma · Source last updated 2012-01-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
years
Interval / dispersion
Full Range
Time frame
Baseline(transplantation) to disease progression or death for any reason, up to 6 years.

What was measured

Average number of years for survival post transplant where overall survival time is measured from date of transplant to disease progression or death for any reason.

Analysis population: Analysis by protocol

Groups in this outcome

Busulfan + Melphalan

Busulfan 32 mg/m\^2 intravenous (IV) for 1 Day then 130 mg/m\^2 IV for 4 Days; and Melphalan 70 mg/m\^2 IV for 2 Days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Busulfan + Melphalan164

Reported measurements

Source class 1
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Busulfan + Melphalan3Not reported0.16Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.1
        upper Limit
        6
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      164
    units
    Participants
description
Average number of years for survival post transplant where overall survival time is measured from date of transplant to disease progression or death for any reason.
dispersion Type
Full Range
groups
  1. description
    Busulfan 32 mg/m\^2 intravenous (IV) for 1 Day then 130 mg/m\^2 IV for 4 Days; and Melphalan 70 mg/m\^2 IV for 2 Days
    id
    OG000
    title
    Busulfan + Melphalan
param Type
MEAN
population Description
Analysis by protocol
reporting Status
POSTED
time Frame
Baseline(transplantation) to disease progression or death for any reason, up to 6 years.
title
Average Overall Survival Time
type
PRIMARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice